Medicine and Dentistry
Prospective Cohort Study
33%
Serotype
33%
Health Care Cost
26%
Streptococcus pneumonia
22%
Pneumococcal Pneumonia
22%
Human Respiratory Syncytial Virus
21%
Streptococcus
21%
Pathogen
20%
Nonoxinol 9
18%
Infection
18%
Nerve Conduction Study
18%
Azithromycin
16%
Compound Muscle Action Potential
16%
Virus Etiology
16%
Respiratory Tract Infection
16%
Transcriptomics
16%
Tuberculosis Treatment
16%
Salmonella
16%
Motor Nerve
16%
Tuberculosis Diagnosis
16%
Child Health
16%
Low and Middle Income Countries
16%
Prospective Study
16%
Interferon Gamma Release Assay
16%
Delayed Diagnosis
16%
Clinical Guideline
16%
Health Care Facility
16%
Nerve Excitability
16%
Clinical Management
16%
Thorax Radiography
16%
Electrophysiology
16%
Health System
16%
Cohort Analysis
16%
Ganglioside GM1 Antibody
16%
Cohort Effect
16%
Artificial Respiration
16%
Respiratory Failure
16%
Patient Monitoring
16%
Community-Acquired Pneumonia
16%
Conjugate
16%
Virus
16%
Case-Control Study
16%
Salmonella Enterica Serovar Typhi
13%
Sputum
11%
Triage
11%
Weakness
9%
Sensitivity and Specificity
9%
Pneumococcus
8%
Childhood Mortality
8%
Nerve Block
8%
Immunology and Microbiology
Campylobacter Jejuni
75%
Guillain-Barré Syndrome
58%
Serotype
37%
Escherichia coli
33%
Plasmid
26%
Extended Spectrum Beta Lactamase Producing Enterobacteriaceae
19%
Prevalence
18%
Epitope
18%
Immunoglobulin G
18%
Humoral Immunity
16%
Ganglioside GM1 Antibody
16%
Sputum
16%
Transcriptomics
16%
Virus
16%
Staphylococcus Aureus
16%
Pneumococcus
16%
Regulatory T Cell
16%
Real Time Polymerase Chain Reaction
16%
Intravenous Immunoglobulin
16%
Peptoclostridium difficile
16%
Streptococcus pneumonia
15%
Titer
11%
Antimicrobial Resistance
11%
Cytotoxicity
10%
Enteritis
9%
Antiganglioside Antibodies
9%
Single Nucleotide Polymorphism
8%
Cytomegalovirus Infection
8%
Blood Plasma
8%
Immunoadsorption
8%
Mycobacterium Smegmatis
8%
Cranial Nerve
8%
Drug Megadose
8%
Screening Test
8%
Real-Time Polymerase Chain Reaction
8%
Immunocompromised Patient
8%
Immunoglobulin
8%
Coinfection
7%
One Health
6%
Population Structure
5%
Pharmacology, Toxicology and Pharmaceutical Science
Syndrome
100%
Campylobacter Jejuni
50%
Salmonella Enterica Serovar Typhi
33%
Antimicrobial Resistance
33%
Prospective Cohort Study
19%
Observational Study
16%
Biological Marker
16%
Immunoglobulin
16%
Respiratory Tract Infection
16%
Case-Control Study
16%
Virus Etiology
16%
Respiratory Failure
16%
Streptococcus pneumonia
11%
Multidrug Resistance
10%
Defined Daily Dose
10%
Cotrimoxazole
10%
Mixed Infection
8%
Cytokine
8%
Diseases
8%
Typhoid Fever
6%
Azithromycin
6%
Ciprofloxacin
6%
Human Respiratory Syncytial Virus
5%
Adenoviridae
5%
Streptococcus
5%
Infectious Agent
5%
Haemophilus Influenzae Type B
5%
